Inside-Out Beauty: The Logic—and Risks Behind Honasa's Fluence Bet

Honasa Consumer's latest acquisition looked modest on paper. The parent company of Mamaearth announced last week that it would acquire a 58% stake in nutraceuticals company Fluence Pharma at an enterprise value of around ₹135 crore, with plans to acquire the remaining stake over the next five to seven years.

Yet the market's initial response was anything but enthusiastic. Honasa shares fell nearly 4% following the announcement before recovering some ground in subsequent sessions.

The reaction raises an important question: what exactly worried investors?

The answer appears to lie less in the economics of the transaction and more in what the acquisition signals about Honasa's next chapter.

For the past two years, the company has been focused on restoring investor confidence after a difficult period marked by inventory corrections, slowing growth, and questions around its offline distribution strategy. That effort appears to have paid off. In its fourth-quarter earnings, Honasa reported 28% year-on-year like-for-like revenue growth, its third consecutive quarter of more than 20% growth, alongside improving profitability and a maiden dividend announcement.

Against that backdrop, investors had begun rewarding management for execution discipline and focus. The Fluence acquisition, however, introduced a new variable: expansion beyond beauty and personal care into nutraceuticals.

"The market's reaction is not entirely surprising," an investor at a venture capital firm told OPEN on condition of anonymity. "Investors generally reward consumer companies for predictable execution within their core categories, while acquisitions—especially into adjacent segments—introduce an element of uncertainty."

The concerns are understandable. Consumer investors tend to be particularly sensitive to capital allocation decisions, especially when companies venture into categories that sit outside their established expertise.

While Honasa's management has positioned nutraceuticals as a natural extension of its beauty business, investors are still assessing whether the company can build a meaningful presence in a category with different consumer behaviors, competitive dynamics, and regulatory considerations.

"I believe it is a combination of valuation, integration risks and category expansion concerns," the investor said. "Whenever a company moves beyond its core business, the burden of proof becomes higher."

Yet the acquisition itself is not obviously expensive.

Fluence generated approximately ₹40 crore in revenue in FY26 and reported EBITDA margins exceeding 20%. The transaction values the company at roughly 3.4 times revenue and 15 times EBITDA—multiples that many analysts would consider reasonable for a profitable, founder-led consumer health business.

That suggests valuation may not be the primary issue.

Instead, investors appear to be evaluating whether the deal represents a logical extension of Honasa's existing strategy or the beginning of a broader diversification push.

Interestingly, management had been laying the groundwork for this move well before the acquisition announcement.

During Honasa's Q4FY26 earnings call in May, co-founder and CEO Varun Alagh spoke extensively about what he described as the rise of "inside-out beauty"—the idea that consumers increasingly seek solutions that combine topical products with ingestible supplements to address concerns such as hair fall, acne, and skin health.

The company's acquisition presentation echoes that thesis, arguing that while the last decade belonged to active skincare, the next decade will be defined by a combination of actives and nutraceuticals as consumers seek solutions that address underlying causes rather than just visible symptoms.

Viewed through that lens, Fluence appears less like a diversification play and more like an attempt to deepen Honasa's participation in categories where it already has a presence.

The strategic overlap is particularly evident with The Derma Co., Honasa's active skincare brand and one of its fastest-growing businesses. Fluence's portfolio of condition-specific supplements, distributed through a network of more than 3,000 dermatologists, could potentially complement topical skincare offerings aimed at the same consumer problems.

"From a strategic standpoint, the fit makes sense," the investor said. "The boundaries between beauty, wellness, preventive health and nutrition are increasingly blurring. Consumers today are not just looking for products that improve appearance externally; they are also investing in solutions that support health and wellbeing from within."

However, the acquisition is about more than simply adding a profitable business.

Honasa has simultaneously announced plans to build a consumer-facing nutraceuticals franchise through a newly incorporated subsidiary, Honasa Health. Management has outlined an ambition to create a ₹500-crore nutraceuticals business over time.

That ambition may be precisely what unsettled investors.

Building a consumer nutraceutical brand requires significant investment in education, marketing, product development, and distribution. Even if Fluence itself is profitable, investors will be watching closely to see whether expansion into wellness affects Honasa's broader margin trajectory or diverts management attention from its core portfolio.

"The real opportunity lies in leveraging Honasa's strengths—brand building, digital marketing, consumer insights and distribution—to scale Fluence more efficiently than it might have been able to on its own," the investor noted. "However, success will ultimately depend on execution discipline. Acquisitions create value when synergies are realized in practice, not merely identified on paper."

For now, the deal remains relatively small in the context of Honasa's overall business. The company generated more than ₹200 crore in annual profit in FY26 and continues to operate with strong cash generation.

That gives management room to experiment.

But investors are unlikely to judge the acquisition on announcement-day presentations or strategic narratives alone.

Instead, they will be watching for tangible evidence over the next 12 to 24 months: revenue growth in the nutraceuticals business, repeat purchase rates, profitability, cross-selling opportunities, and whether Fluence can become meaningfully accretive to the broader portfolio.

Ultimately, the market is not debating whether Fluence is a good ₹40-crore business.

It is debating whether Honasa can successfully evolve from a beauty-focused company into a broader wellness platform without compromising the growth, profitability and execution discipline that investors have only recently begun to reward. One challenge, however, is whether dermatologists will embrace a brand that moves from clinic-led recommendations to mass-market distribution. In our earlier interview, Fixderma founder Shaily Mehrotra noted that many dermatologists are protective of the products they recommend and are often uncomfortable when those products become widely available on e-commerce and quick-commerce platforms. For brands built on medical credibility, broader accessibility can sometimes come at the cost of exclusivity and professional trust.